Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Roblox Lawsuit Families are filing Roblox lawsuits after children were targeted by predators for grooming, sextortion, sexual abuse, or exploitation on the platform. Learn who qualifies, what cases allege, and how to file a confidential claim.
Dupixent Lawsuit Dupixent lawsuits are being investigated for patients who developed rare blood cancers such as cutaneous T-cell lymphoma (CTCL) after receiving injections, alleging that Sanofi and Regeneron failed to warn about the potential risks of immune suppression and delayed cancer diagnosis.
Tabletop Fire Pit Lawsuit Individuals who suffered severe burns, or families who lost a loved one in a tabletop fire pit explosion, may be eligible for financial compensation through a fire pit injury lawsuit.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Lawsuits Over Losartan, Irbesartan Consolidated With Valsartan Recall Claims December 26, 2019 Irvin Jackson Add Your Comments A panel of federal judges has determined that all losartan lawsuits and irbesartan lawsuits filed in U.S. District Courts nationwide should be consolidated with the pending valsartan litigation, since each of the claims involve similar allegations that cancer-causing chemicals contaminated the generic blood pressure drugs. There are currently more than 150 product liability lawsuits and class action claims pending in the federal court system that have resulted in valsartan recalls issued since July 2018, after it was discovered that certain generic drug makers distributed pills that contained N-nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA) and other chemicals that are known to increase the risk of cancers. Many of the complaints allege individuals developed various cancers following long-term exposure to the chemical, including liver cancer, stomach cancer, small intestine cancer, esophageal cancer, prostate cancer, pancreatic cancer and other cancers. VALSARTAN LAWSUITS Were you prescribed contaminated Valsartan drugs? Side effects of recalled valsartan may increase the risk of cancer, due to an impurity discovered in certain generic versions of the hypertension drug. Learn More SEE IF YOU QUALIFY FOR COMPENSATION VALSARTAN LAWSUITS Were you prescribed contaminated Valsartan drugs? Side effects of recalled valsartan may increase the risk of cancer, due to an impurity discovered in certain generic versions of the hypertension drug. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Given common questions of fact and law raised in valsartan lawsuits, the U.S. Judicial Panel on Multidistrict Litigation (JPML) previously decided to consolidate and centralize all pretrial proceedings before U.S. District Judge Robert B. Kugler in the District of New Jersey earlier this year, and it is widely expected that several thousand valsartan cancer claims will ultimately be presented in the coming months and years. In addition to problems with valsartan, similar recalls have also been issued by manufacturers of other generic blood pressure drugs which are part of the same class of medications, known as angiotensin II receptor blockers (ARBs), including losartan and irbesartan. Investigations suggest changes in the generic drug making process for the blood pressure and hypertension drugs resulted in the production of the chemical byproduct discovered over the past year. In September, plaintiffs filed a motion to include claims involving cancer diagnosed following exposure to losartan, irbesartan or other ARBs in the valsartan MDL, indicating there are overlapping issues in the cases, including many situations where plaintiffs switched between various different types of blood pressure drugs found to contain NDM, NDEA or other cance-rcausing chemicals. Although the drug makers opposed consolidating the cases, in a transfer order (PDF) issued December 18, the JPML determined it was appropriate to consolidate the cases, but limited the inclusion to only irbesartan and losartan, instead of all ARBs. As a result of the decision, four additional lawsuits have been added to the MDL, but that number is expected to grow with future filings of irbesartan and losartan claims. “The losartan and irbesartan actions present common questions of fact arising from the allegation that the same or substantially similar manufacturing processes are used in the production of valsartan, losartan, and irbesartan and result in the formation of nitrosamine impurities in the same manner,” the panel wrote in its decision. “Thus, the valsartan, losartan, and irbesartan actions will present common factual questions as to the cause of the nitrosamine impurities and, in particular, alleged common defects in the manufacturing process; when defendants knew or should have known of the impurities; and whether the amounts of nitrosamines in the medications presented a risk of cancer or other injuries.” As part of the coordinated pretrial proceedings, it is expected Judge Kugler will establish a “bellwether” process, where the parties will use the fact sheet information about each valsartan cancer claim to select a representative group cases, which will be prepared for early trial dates in the MDL. While the outcome of these early “bellwether” trials will not be binding on other plaintiffs, they are typically scheduled in complex pharmaceutical litigation to help the parties gauge how juries may respond to evidence and testimony which will be repeated throughout the litigation, and facilitate potential valsartan cancer settlements with the manufacturers and distributors of the contaminated pills. Written by: Irvin Jackson Senior Legal Journalist & Contributing Editor Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends. Tags: Cancer, Drug Recall, Hypertension, Irbesartan, Losartan, NDEA, NDMA, Valsartan More Valsartan Lawsuit Stories Generic Valsartan Manufacturer Accused of Hiding Key Documents in Lawsuits Over Contaminated Pills September 8, 2025 Daubert Hearings for Valsartan Cancer Lawsuit Bellwether Trials to Begin Aug. 26 August 19, 2025 Schedule Leading to Valsartan Lawsuit Bellwether Trial in September 2025 Outlined by MDL Judge July 16, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermFacebookThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Brain Tumor Symptoms Create Lifelong Meningioma Fears Among Women (Posted: today) Women across the U.S. are now pursuing product liability lawsuits and medical monitoring class action claims to secure compensation for potential brain tumor symptoms and side effects linked to the use of Depo-Provera. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (09/03/2025)Pfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025) Safety Problems With Roblox and Discord Endangered Young Girl: Lawsuit (Posted: 2 days ago) A Texas mother is pursuing a lawsuit against Roblox and Discord, claiming the design of the apps allow sexual predators to access and groom young children. MORE ABOUT: ROBLOX LAWSUITLawsuit Alleges Roblox Lacks Safeguards To Protect Children From Sexual Predators (09/11/2025)Roblox Age Verification Technology To Be Implemented Amid Child Exploitation Lawsuits (09/09/2025)Roblox Kidnapping Lawsuit Filed After Child Was Abducted and Sexually Trafficked (09/03/2025) Dupixent Cutaneous T-Cell Lymphoma Warning Label Update Being Evaluated by FDA (Posted: 3 days ago) Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer. MORE ABOUT: DUPIXENT LAWSUITDupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (09/04/2025)Dupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025)
Generic Valsartan Manufacturer Accused of Hiding Key Documents in Lawsuits Over Contaminated Pills September 8, 2025
Schedule Leading to Valsartan Lawsuit Bellwether Trial in September 2025 Outlined by MDL Judge July 16, 2025
Depo-Provera Brain Tumor Symptoms Create Lifelong Meningioma Fears Among Women (Posted: today) Women across the U.S. are now pursuing product liability lawsuits and medical monitoring class action claims to secure compensation for potential brain tumor symptoms and side effects linked to the use of Depo-Provera. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (09/03/2025)Pfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)
Safety Problems With Roblox and Discord Endangered Young Girl: Lawsuit (Posted: 2 days ago) A Texas mother is pursuing a lawsuit against Roblox and Discord, claiming the design of the apps allow sexual predators to access and groom young children. MORE ABOUT: ROBLOX LAWSUITLawsuit Alleges Roblox Lacks Safeguards To Protect Children From Sexual Predators (09/11/2025)Roblox Age Verification Technology To Be Implemented Amid Child Exploitation Lawsuits (09/09/2025)Roblox Kidnapping Lawsuit Filed After Child Was Abducted and Sexually Trafficked (09/03/2025)
Dupixent Cutaneous T-Cell Lymphoma Warning Label Update Being Evaluated by FDA (Posted: 3 days ago) Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer. MORE ABOUT: DUPIXENT LAWSUITDupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (09/04/2025)Dupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025)